Late-Stage Drug Trials Offer New Hope for PTSD

Doctor consulting a patient at a desk — Photo: Branislav Nenin / Shutterstock

After a quarter century with no new post-traumatic stress disorder medicines, late-stage drug trials are finally stacking up.

Story Snapshot

Only sertraline and paroxetine have Food and Drug Administration approval for post-traumatic stress disorder.
A 2025 review found eight post-traumatic stress disorder drugs in phase three trials.
Pipeline summaries list candidates like brexpiprazole, ketamine, MDMA, propranolol, and Silexan.
The Food and Drug Administration signaled new attention to mental health products, including post-traumatic stress disorder.

What the Food and Drug Administration Has Approved So Far

Food and Drug Administration records and medical guidance show only two approved medicines for post-traumatic stress disorder: sertraline and paroxetine. Sertraline gained approval in 1999, and paroxetine followed in 2001. No new medicine has won approval for this condition since then. That long gap set the stage for heavy off-label use and many small studies that did not change the label. These facts are consistent across federal and clinical sources.

Review articles describe this period as one of high need and slow progress. Doctors often tried other antidepressants or symptom-focused drugs. Many did not show strong or consistent benefit in large trials. This record made post-traumatic stress disorder a hard target for drug makers. Companies faced high costs, complex patients, and tough endpoints. As a result, few programs reached the final stage of testing, and none cleared the approval bar for over two decades.

What Is Now in Late-Stage Development

A 2025 systematic review reported eight drug programs for post-traumatic stress disorder in phase three trials. That count shows real momentum after years of limited options. Phase three is the stage that can support approval if results are strong and safe. The review did not judge which ones will win, but it confirmed active, late-stage work across this field at that time. That marks a notable shift in the pipeline’s scale.

A 2024 pipeline table named several specific candidates and mechanisms under study. Examples include brexpiprazole, ketamine, MDMA, propranolol, and Silexan, each with different targets or uses. Some are repurposed drugs tested for new benefits. Others are novel approaches that aim to reshape care models. These programs vary in design, dosing, and safety needs. Together, they show a wider search for ways to cut core symptoms and improve daily function.

Renewed Regulatory Signals and Why They Matter

Federal actions suggest rising focus on serious mental illness, including post-traumatic stress disorder. The Food and Drug Administration announced steps to speed treatments after an executive order, and it highlighted products tied to trauma-related care. These steps do not guarantee approval. They do show attention to faster review paths and tools that can move strong programs forward. That matters when the standard toolbox has not changed in decades.

Even with this movement, experts caution that phase three status alone does not predict success. Late-stage trials test whether benefits are clear, repeatable, and safe for broad use. Many psychiatric drugs fail at this hurdle. Some need more studies to confirm effects. Others raise safety questions or show benefits that are too small. The record in post-traumatic stress disorder fits this pattern, with long gaps between early promise and a label that patients can rely on.

What Patients and Families Should Watch Next

Patients should track final readouts from phase three trials, not just press releases. Clear gains on validated scales, lower dropout rates, and safe profiles are key signs. Therapies that show durable relief across different groups matter most. Doctors and patients will also look for real-world fit. Ease of use, side effects, and access can decide whether a new drug helps daily life beyond the clinic.

The rumor has a real event behind it: Resilient Pharmaceuticals, the former Lykos, resubmitted the MDMA NDA for PTSD in August, without running the new Phase 3 the 2024 CRL asked for. October is only reachable on an accelerated track, since an ordinary resubmission clock lands in… pic.twitter.com/ltiQncSVrq

— Cristiano Augusto Tofani (@AugustoTofani) August 29, 2026

For many Americans, this story touches deeper worries about a system that moves too slowly while people suffer. Veterans, first responders, and trauma survivors have waited years for better options. The federal process must guard safety and proof, but it also must respond to urgent need. If the current late-stage wave delivers, it could mark the first real update to approved post-traumatic stress disorder medicines since 2001 and bring hope to families across the country.